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Abstract:  In  vivo  optical  Imaging  is  an  inexpensive  and  highly  sensitive  modality  to 
investigate and follow up diseases like breast cancer. However, fluorescence labels and 
specific tracers are still works in progress to bring this promising modality into the clinical 
day-to-day use. In this study an anti-MUC-1 binding single-chain antibody fragment was 
screened,  produced  and  afterwards  labeled  with  newly  designed  and  surface  modified 
NaYF4:Yb,Er upconversion nanoparticles as fluorescence reporter constructs. The MUC-1 
binding of the conjugate was examined in vitro and in vivo using modified state-of-the-art 
small animal Imaging equipment. Binding of the newly generated upconversion nanoparticle 
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based probe to MUC-1 positive cells was clearly shown via laser scanning microscopy and 
in an initial proof of principal small animal optical imaging approach. 
Keywords:  anti-MUC-1  single-chain  antibody  fragment;  upconversion  nanoparticles; 
labeling; in vivo optical molecular imaging 
 
1. Introduction 
There is  a great demand for new fluorescent labeling materials due to the rapid advantages in 
monitoring and diagnose of diseases, and thus the development of more efficient and ultrasensitive 
fluorescent labels is becoming a forceful trend. In addition, optical molecular imaging is a desirable 
technique for non-invasive in vivo diagnostics and follow-up, since it is a highly sensitive, inexpensive 
imaging method that can potentially resolve relevant target structures in vivo [1]. With the injection of 
a fluorescent reporter—also named probe—optical imaging allows specific tagging of, e.g., receptors, 
antigens,  genes,  or  drugs,  and  thereby  leadings  to  a  better  understanding  of  molecular  disease 
processes [1–4]. Addressing overexpressed gene products like aminopeptidase N-α-V-β-3 or MUC-1 
in (breast) cancer tumor cells is highly recommendable for optical imaging approaches, since these are 
also prognostic markers [5–9]. Furthermore, MUC-1 expression correlates with cancer severity and is 
inversely correlated to patients’ survival prognosis [6]. 
Apart  from  the  today  well-known  band-emitting  quantum  dot  systems  [10–12],  the  use  of 
upconversion  particles  has  attracted  the  attention  of  several  research  groups.  In  this  case,  the 
luminescence depends on dopant ions of the rare earth elements occupying specific lattice sites of the 
material. A further benefit of such systems is the absence of well-known toxic elements like cadmium 
and selenium [8,13,14] as well as not suffering from high photobleaching rate or being vulnerable to 
metabolic or chemical degradation [15]. A couple of in vitro assays have been described [16,17] and 
furthermore  some  initial  in  vivo  tests  are  known  [9,18].  Upconversion  nanoparticles  convert  near 
infrared radiation (NIR) into visible emission by a multiphoton absorption process, which involves 
metastable  excited  states  only.  Since  the  lifetime  of  these  metastable  states  is  in  the  range  of 
microseconds, the two or more NIR photons required for the excitation of the emitting state can be 
absorbed sequentially rather than simultaneously. Excitation in the NIR at low excitation densities 
provides some significant advantages compared to excitation in the UV/visible spectral range. For 
instance,  any  luminescence  excited  in  the  sample  by  the  NIR  light  will  be  emitted  at  a  longer 
wavelength  and  therefore  not  in  the  visible  range.  This  strongly  reduces  the  autofluorescence 
background,  in  biological  materials  leading  to  a  simplified  detection  of  the  emitted  light  and  an 
increased sensitivity [19]. Furthermore, there is no need for time-resolved detection due to the large 
wavelength separation between excitation and emission. Moreover, excitation in the NIR decreases 
photo degradation of the biomaterials and may simplify in vivo imaging because of the ability of NIR 
radiation to penetrate more deeply into biological tissue. The emission of an upconversion material 
depends on the choice of rare-earth ion doped into the crystal lattice of the material and on local 
properties of the respective lattice sites. In contrast to quantum dots the optical properties do therefore 
not depend on the particle size except that dopant ions in surface sites usually display lower quantum Int. J. Mol. Sci. 2012, 13  4155 
 
 
yield and different crystal splitting of their emission lines. Highly efficient upconversion processes are 
observed only in host materials with low photon energies, i.e., for materials where the probability for 
non-radiative multiphonon relaxation processes is low. The best host material for upconversion known 
today is NaYF4 doped with the ion couples Yb
3+/Er
3+ or Yb
3+/Tm
3+ [20]. The synthesis of nanocrystals 
of these materials has therefore attracted a great deal of interest and a variety of methods have been 
developed [21–23]. In these materials, the NIR excitation light of 974 nm is absorbed mainly by the 
Yb
3+-ions and subsequently transferred to the co-dopant. In the case of co-doping with trivalent erbium, 
the energy of two excited Yb
3+-states is transferred to one Er
3+-ion, resulting in emission mainly in the 
green and the red spectral range. Especially the red emission is beneficial for in vivo optical imaging; 
thus  a  single-chain  Fv  fragment  targeting  the  MUC-1  receptor  was  labeled  to  surface  modified 
upconversion nanoparticles and used for fluorescence optical in vitro and a proof of concept in vivo 
molecular imaging approach. 
2. Results and Discussion 
The NaYF4:Yb,Er-nanocrystals  used in  this  study  were synthesized in  the coordinating solvent  
2-hydroxyethyl-ethylenediamine [5]. The X-ray diffraction data of nanocrystal powders indicate that 
the nanoparticles crystallize in the cubic α-phase (Figure 1A). From the peak width a mean particle 
size of 25 nm was calculated with the Debye-Scherrer equation. This was according to the TEM 
images of the particles displaying a rather broad particle size distribution (Figure 1B). As usual for 
Yb
3+/Er
3+-doped  upconversion  materials,  the  emission  bands  are  located  at  about  405  nm  (blue),  
550 nm (green) and 660 nm (red) upon excitation at 974 nm (Figure 1C). The appropriate transitions 
are given in the Figure 1C. The intensity of the blue emission band is rather low, since the emitting 
level is populated by a sequential three photon step. 
After synthesis the surface of the particles had to be modified in order to allow the attachment of 
the anti-MUC-1-single chain Fv antibody fragment (M12) as well as to ensure a stable dispersion of 
these nanoparticles in biocompatible media, e.g., PBS buffer. Since a covalent binding is less suitable 
for NaYF4 surfaces, secondary interactions had to be taken into account for the attachment of the 
linker. After synthesis the particles were stabilized in aqueous dispersion by the negatively charged 
HEDP [24]. This low-molecular weight compound is only loosely attached to the particle surface. 
Zeta-potential titrations of particle dispersions showed that the surface charge had shifted to positive 
values after washing with water pointing to a removal of HEDP (Figure 2). Nevertheless, electrostatic 
interactions can be utilized to bind oppositely charged molecules to the particle surface if the molecule 
possesses  a  multitude  of  likely  charged  centers.  Coating  of  the  washed  positively  charged 
upconversion nanoparticles (ucNPs) with polyacrylic acid (PAA) of medium molecular weight via 
electrostatic interaction renders the surface hydrophilic enough to stabilize the particles in PBS buffer 
as also recently published elsewere [25–27]. Furthermore, PAA provides carboxylic groups [28] to 
allow  the  coupling  of  proteins  or  peptides  via  standard  EDC/sulfo-NHS  reaction.  The  strong 
attachment of PAA to the ucNPs was proven by measurements of the electrophoretic mobility. The 
zeta-potential changes from +20 mV (pH 5) for the washed uncoated particles to −32 mV (pH 5) after 
PAA coating and subsequent thorough washing. TEM measurements verify that the particles do not 
agglomerate during polymer coating (data not shown). However, the polymer coating can hardly be Int. J. Mol. Sci. 2012, 13  4156 
 
 
seen in the TEM images. Statistical analysis on particle size revealed a mean diameter of 34 ±  11 nm. 
Similar to the results obtained with uncoated particles (see also Figure 1C) the emitted light of the 1.9% 
PAA-surface-modified particles exhibited a very low green-to-red ratio, i.e., a much higher intensity of 
the emission band centered at about 670 nm compared to that at about 550 nm. 
Figure 1. (A) X-ray powder diffraction pattern of NaYF4:Yb,Er (a; black line) with the 
corresponding  JCPDS  No.  77-2042  line  pattern  for  α-NaYF4  (b;  red  line).  
(B) Transmission electronic micrograph of the unconjugated, un-modified upconverting 
nanoparticles. Scale bars are indicated in the picture. (C) Photoluminescence spectra of the 
upconversion nanoparticles in aqueous colloidal solution (excitation with a 974 nm laser). 
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Figure 2. Zeta-Potential versus pH for aqueous dispersions of upconversion nanoparticles 
after synthesis (solid squares) and after washing (solid triangles) to remove HEDP. 
 
The  PAA-modified  NaYF4:Yb,Er  particles  were  then  labeled  to  the  anti-MUC-1-single  chain  
Fv antibody fragment (M12) for fluorescence imaging. The used M12 was produced as described in 
the Experimental Section with a purification rate of >95% as shown in both SDS page as well as 
Western blot analyses (see also Figure 3B), which reflects the purification rates obtained elsewhere [21]. 
The EDC-mediated labeling reaction result in  M12-ucNP  conjugates showing the  respective blue, 
green and red fluorescence spectra with similar intensities compared to the original and PAA-modified 
upconversion  nanparticel  (ucNP)  solution.  Obviously,  the  ucNPs  do  not  agglomerate  during  the 
labeling reaction as visible in Figure 4A, showing the hydrodynamic diameter of the conjugates and 
non-labeled ucNP reference particles. The conjugates are labeled with about 15 units M12 single-chain 
Fv fragments per particle. This was roughly estimated from the specific M12-absorption at 280 nm 
(εM12~44.3 kM
−1cm
−1) using the 100 k-filtrates of the conjugates and the unlabeled M12 reference  
(see Figure 4B). 
The underglycosylated MUC-1 receptor is one of the key-players in breast cancer formation and 
thus highly overexpressed [29,30]. To validate the synthesis of the MUC-1 receptor different human 
cancer cells had to be checked: The MDA-MB-231 and BT-20 breast cancer cell lines exhibited high 
MUC-1  expression  while  HT-1080  showed  no  detectable  MUC-1  production  (see  Material  and 
Methods).  In  addition,  cell  binding  studies  by  FACS  showed  specific  binding  to  the  MDA  cells 
expressing MUC-1, whereas the non-expressing control cell line showed no binding (see Figure 3A). 
Thus, MDA-MB-231 cells were chosen as positive while HT-1080 cells served as negative controls. 
A distinct binding of the M12-ucNP construct to the MUC-1 receptor exhibiting cells was shown  
in  microscopic  studies  (Figure  5).  Upconversion  nanoparticles  (ucNP)  without  targeting  units  
(i.e., without M12) neither bound to MDA-MB-231 nor HT-1080 cells, respectively (data not shown). 
In addition, nearby no binding to MUC-1 receptor negative HT-1080 cells was observed (Figure 5), 
thus  showing the specificity of M12-ucNP  binding to  only  MUC-1  receptor overexpressing cells. 
Those findings are congruent to recently published results with PAA-modified ucNP from Jin et al. [25] 
where a highly reduced cell uptake was observed after PAA treatment. Xiong et al. [8] and Zako et al. [9] 
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both  developed  upconversion  particles  that  were  labeled  to  cyclic  RGD  peptides  addressing  
tumor-derived  α-V-β-3  overexpression.  In  their  microscopic  experiments  the  specific  binding  was  
also shown. 
Figure 3. Characterization of the recombinant single-chain Fv fragment M12. (A) Binding 
properties of the anti-MUC-1 M12 to cells by flow cytometry. Cells were incubated with 
purified M12-scFv (transparent curves) or with PBS as negative control (red curves). No 
binding was detected at the MUC-1 negative cell line (left) while MUC-1 expressing cell 
line  MDA-MB-231  showed  clear  binding  of  the  M12-scFv  (right).  (B)  Molecular  size 
chromatography sample of the recombinant single-chain Fv fragment M12 documented by 
SDS-PAGE  (left)  and  immuno-staining  (Western  blot,  right),  immunodetection:  1st 
antibody: anti-His (Qiagen AG, Germany); 2nd antibody: alkaline-phosphate-conjugated 
anti mouse-IgG moab 3. Staining: substrate 5-bromo-4-chloro-3 indoyl-phosphate (BCIP) 
was used in conjugation with the enhancer, nitro blue tetrazolium (NBT). 
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Figure  4.  (A)  Hydrodynamic  diameter  of  the  conjugates  (red)  and  the  unconjugated 
upconversion nanoparticle reference (blue) after 100 kDa-purification, both in PBS (pH 7.4). 
(B)  Absorption  spectra  of  the  labeling  mixture  (M12-ucNP;  red)  and  M12-reference  
(M12; grey) after 100 kDa-purification. 
 
Figure  5.  Laser  scanning  microscopy  of  MDA-MB-231  and  HT-1080  cells  after 
incubation  with  anti-MUC-1-ucNP  conjugates  (20× ).  Binding  to  MDA-MB-231  was 
visible in the fluorescence channel while no binding to HT-1080 could be observed. 
 
To  check  the  ucNPs’  suitability  for  near  infrared  in  vivo  optical  imaging  unlabeled  and  
M12 labeled ucNPs were injected intramuscular into nude mice and imaged. In both cases, a clear 
fluorescence  signal  could  be  observed  (300  s,  f-stop  2.5,  Figure  6A).  Based  on  those  results  
MDA-MB-231  adenocarcinoma  cells  were  implanted  into  a  nude  mouse  and  subjected  to  in  vivo 
imaging. Binding of the M12-ucNP to the MUC-1 receptor expressed by the MDA-MB-231 tumor 
cells resulted in a fluorescent signal while the surrounding tissue was non-fluorescent (Figure 6B) Int. J. Mol. Sci. 2012, 13  4160 
 
 
likewise observed by Yu et al. [31] when using a chlorotoxin-labeled upconversion nanoparticle for 
tumor imaging. However, the high energy-input and time that was required for imaging in our case 
resulted later in an actinocutitis which was comparable to a sunburn. This observed actinocutitis based 
on the time-based high-energy input (300 s, 30 mW at 978 nm constant laser light) and also the high 
concentrations of probe needed (1 mM) still shows the limitations that are based on (i) the recently 
available instrumentation as well as the (ii) the used M12-ucNP probe design. Using microscopic 
approaches  on  transparent  HeLa  cells  resulted  in  a  higher  signal-to-noise  ratio  when  increase  the 
excitation power [32]. In our approach, the use of light pulses with pulse durations in the microsecond 
to nanocecond range instead of continuous wave excitation is supposed to reduce the energy input but 
not violate the fluorescence signal and thus might reduce the negative side effects dramatically by also 
increasing the signal-to-noise ratio. Also the use of high resolution, cooled, back-illuminated CCD 
cameras  with  a  high  quantum  efficiency  (QE)  like  the  recently  available  4  MP  back-illuminated 
Xtreme camera system that provide a QE of >95% (Carestream Molecular Imaging) or by use of 
modern EMCCDs [8] should increase the detection limit and thus avoid the observed side-effects. 
Further developments of the ucNPs regarding their fluorescence yield, e.g., by using ucNP with a  
non-doped shell (core-shell nanoparticles) may also increase the signal-to-noise ratio and thus allow 
shorter imaging times as well lower  probe concentrations.  Increasing the red-to-green ratio of the 
emission might further improve that approach.  
Figure 6. In vivo optical molecular imaging proof-of-principal approach in nude mice. 
Intensities are given in arbitrary units (AU). Imaging parameters were 300 s, f/2.5, 30 mW 
978 nm laser light source, 850 cut of NIR filter in an modified MS FX PRO small animal 
in vivo imaging system (Carestream Molecular Imaging). (A) Fluorescence imaging of 
unlabeled upconversion  nanoparticles (ucNP) injected into the muscle of a mouse leg.  
(B) Anti-MUC-1-ucNP  based signal  of the MDA-MB-231 xenograft. The fluorescence 
signal was pseudo-colored and overlayed to a white light reference image.  
 
However,  the  developed  approach  is  of  use  because  patients  who  are  at  high  risk  to  develop,  
e.g., breast cancer [33] express the MUC-1 antigen at an early stage. Thus, early cancer detection, Int. J. Mol. Sci. 2012, 13  4161 
 
 
staging and treatment-follow up via imaging is highly beneficial and had been shown previously with a 
dual  labeled  MRI/fluorescence  probe  [34].  The  benefit  of  using  upconversion  nanparticles  versus 
classical, e.g., Cyanin dyes is based on the used excitation light that should penetrate the tissue with 
less absorption and thus allow deeper tissue imaging in the future. 
3. Experimental Section 
3.1. Synthesis of Upconversion Nanoparticles 
Water soluble a-phase NaYF4:Yb,Er (20 mol% Yb, 2 mol% Er) nanoparticles were synthesized and 
surface modified with HEDP (hydroxyethyl-diphosphonic acid) according to a published procedure in 
the coordinating solvent N-(2-hydroxyethyl)ethylendiamine (HEEDA) [35]. 
3.2. Surface-Modification of Upconversion Nanoparticles 
For Polyacrylic acid (PAA) coating the nanoparticles stabilized with HEDP were first thoroughly 
washed  with  water  to  remove  the  excess  of  the  organophosphoric  stabilizer  using  centrifugation. 
Afterwards  the  suspension  was  diluted  with  aqueous  HCl  solution  until  a  final  upconversion 
nanoparticle (in short: ucNP) concentration of 0.05% (w/w) and a pH of 2.3 was reached. One hundred 
millilitres of this nanophosphor suspension were added to 100 mL 0.5% aqueous solution of NaPAA 
(pH 9.3, Sigma-Aldrich) and stirred at room temperature for one hour. To remove the unbound PAA 
the nanoparticles were thoroughly washed with water using a stirred ultrafiltration cell equipped with a 
regenerated cellulose membrane (cut-off 100 kDa, Vivascience, Hannover, Germany). 
3.3. Particle Characterization 
For TEM measurements the dispersion was dried on a carbon-coated copper grid and investigated 
by means of a Philips Tecnai 20 transmission electron microscope operating at 200 kV. Up-conversion 
emission spectra of ucNP dispersions were measured with a Fluorolog 3 FL3-22 spectrometer (Horiba 
Jobin  Yvon  GmbH,  Bensheim,  Germany)  combined  with  a  200  mW  IR  laser  module  (Roithner 
Lasertechnik GmbH, Vienna, Austria). Quartz cuvettes containing the samples were placed inside the 
spectrometer and excited by the 980 nm light of the laser. 
Electrophoretic  mobility  of  ucNPs  was  measured  in  dilute  aqueous  dispersions  (0.05%  (w/w))  
by  means  of  90  Plus  and  the  appendant  zeta-potential  module  (Brookhaven  Instruments  Limited, 
Worcestershire,  UK).  The  pH  of  the  dispersions  was  carefully  adjusted  with  HCl  and  NaOH  
solution, respectively.  
3.4. Production of Anti-MUC-1 Single-Chain Fv Fragments 
3.4.1. Propagation of Phage from the Human Single-Chain Fv Phage Display Library 
One liter of 2×  TY, 100 µg/mL ampicillin, 1% (w/v) glucose was inoculated with an aliquobrary 
10
9 diversity glycerol stock. The rescue of the phage was carried out as described in [36]. 
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3.4.2. Selection of Human Single-Chain Fv Fragment 
Human  single-chain  Fv  antibody  fragments  against  the  cancer  antigen  MUC-1  were  selected 
directly on the human breast cancer cell MCF-7 (ATCC: HTB-22). After three rounds of selection, the 
individual bacterial clones were induced to produce soluble anti-MUC-1 single-chain Fv fragments  
(in short: M12). These single-chain Fv fragments were tested on ELISA for their ability to bind to the 
MCF-7 cell line and the MUC-1 core protein [36].  
3.5. Fermentation of Single-Chain Fv Fragments (M12) 
Immunoglobulin variable-region genes (VH and VL) were PCR amplified from 5 mL of cDNA, 
assembled, and cloned into pCANTAB6 as described elsewhere [36]. Plasmids were transformed into 
50  μL  Escherichia  coli  TG-1  by  electroporation  [37].  Fermentations  of  anti-MUC-1  single-chain  
Fv fragments (M12) were carried out in a 7 L working volume stirred tank bioreactor (biobench 7, 
Applikon,  Schiedam,  The  Netherlands)  using  a  synthetic  mineral  medium  (16.6  g/L  KHPO4,  
4  g/L  NH4(H2PO4),  0.07  g/L  CaCl2∙2H2O,  0.15  g/L  FeSO4∙7H2O,  1.5  g/L  MgSO4∙7H2O,  
2.1 g/L citric acid, 0.2 g/L L-arginine, 0.2 g/L L-methionine, 25 mg/L Kanamycin and 25 g/L glucose 
supplemented with 1 mL/L of Ptm1 trace salts (Invitrogen, Darmstadt, Germany, pH 6.8) at 30 ° C and 
constant aeration at 1 L
−1∙min
−1. Fermentations were inoculated with 250 mL of a preculture in LB 
medium grown to an OD of 1.5. When the initial amount of glucose was exhausted, glucose was added 
using the dO2 signal to control the glucose feed rate, until an OD of 20 was reached. At this time, the 
M12-expression was induced by the addition of 0.5 mM IPTG and temperature was lowered to 28 ° C. 
Induction  was  carried  out  for  24  h  until  the  fermentation  was  harvested.  The  M12  single-chain  
Fv  fragments  were  expressed  into  the  periplasm  of  the  E.  coli  strain  and  afterwards  purified  by  
Ni-NTA chromatography. 
3.6. Purification of M12 Single-Chain Fv Fragments 
For  Ni-NTA  affinity  purification  of  M12  fragments,  a  Streamline  25  column  (Pharmacia/GE 
Healthcare, Freiburg, Germany), packed with 100 mL of Streamline Chelating medium (Pharmacia), 
was charged with 3 times the column volume of 50 mM NiSO4 and equilibrated with 10 column 
volume of binding buffer (PBS containing 1 M NaCl, pH 8). Bulk cell mass was separated from the 
fermentation  supernatant  by  centrifugation  (10  min,  10,000  g).  A  1/9  volume  of  10×   PBS  and  
50  g/L  NaCl  was  added  to  a  final  concentration  of  1  M  NaCl,  pH  was  adjusted  to  8,  and  the 
conditioned  fermentation  broth  was  passed  over  the  column  in  expanded  mode  at  a  flow  rate  of  
410 cm/h. The column was then washed in expanded mode with binding buffer until the flow through 
was particle-free. Then the flow was reversed, the flow rate set to 100 cm/h and a 5-column volumes 
wash with binding buffer supplemented with 10 mM imidazole was performed in packed-bed mode. 
Bound  M12  fragments  were  eluted  with  binding  buffer  containing  250  mM  imidazole  and  the  
protein-containing eluate, determined by monitoring the A280, was collected. 
The  M12  single-chain  Fv  fragments  were  purified  by  ion  exchange  (anion  exchange) 
chromatography using MonoS Sepharose (GE Healthcare) on an Äkta FPLC system (GE Healthcare). 
The M12 fragments were eluted with Na-acetate (pH 4.5) and a linear gradient 20–1000 mM NaCl. Int. J. Mol. Sci. 2012, 13  4163 
 
 
Final polishing and endotoxin removal were performed by size exclusion chromatography (SEC) with 
Sepharose 200/300 (GE Healthcare). Recombinant M12 fragments were eluted with PBS (pH 7.4) at a 
flow rate of 1 mL/min. Samples were fractionated and stored for further analysis at 4 ° C. 
SDS-PAGE and Western blotting were performed to determine the M12 fragment quality [38].  
M12 fragments were detected by anti-His mAb (Qiagen, Hilden, Germany). Bound antibody was stained 
with an alkalinephosphatase-conjugated anti-mouse-IgG monoclonal antibody (mAb, Sigma-Aldrich, 
St  Louis,  USA)  and  a  solution  of  Tris-HCl  (pH  8.0)  and  0.2  mg/mL  naphtol-AS-Bi-phosphate  
(Sigma-Aldrich) supplemented with 1 mg/mL Fast-Red (Serva, Heidelberg, Germany). 
3.7. Flow Cytometric Binding Analyses 
Cell-binding activity of M12 fragments was evaluated using a FACSCalibur flow cytometer and 
CellQuest software (Becton Dickinson, Heidelberg, Germany). Cells were stained with the affinity 
purified M12 fragment as described previously. Briefly, 10,000 events were collected for each sample, 
and analyses of intact cells were performed using appropriate scatter gates to exclude cellular debris 
and aggregates. A total of 5 ×  10
5 cells were incubated for 1 h on ice with 50 µL of the M12-bacterial 
protein extract at a concentration of 30–40 µg/mL. The cells were washed with PBS buffer containing 
0.2% (w/v) BSA and 0.05% (w/v) sodium azide and then incubated for 30 min with an anti-His mAb 
diluted 1:2 in PBS buffer. Cells were washed and incubated with FITC-labeled goat-anti-mouse IgG 
(Dako Diagnostica, Hamburg, Germany) for 1 h at 4 ° C. After a final wash, the cells were treated  
with 2 µL of 6.25 mg/mL Propidium Iodid and subsequently analyzed by fluorescence-activated cell  
sorting [38]. 
3.8. Labeling of Upconversion Nanoparticles with Anti-MUC-1 Single-Chain Fv Antibody Fragments 
The  anti-MUC-1  single-chain  Fv  antibody  fragments  (M12)  were  attached  to  
PAA-modified  upconversion  nanoparticles  using  the  popular  cross-linker  carbodiimide  EDC  
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (Sigma-Aldrich, St Louis, USA). EDC mediates the 
formation of amide linkage between carboxylate-equipped ucNPs and amine groups found at the M12 
single-chain Fv fragments. The reaction was performed in a 2 mL Eppendorf-tube by adding 450 µL 
ucNP suspension (approx. 0.2 µM, measured by UV), 82 µL M12 solution (approx. 22 µM) and 70 µL 
PBS (pH 7.4, Sigma-Aldrich). After mixing the educts, 23 µL EDC (10 mM) are rapidly added to the 
stirred solution. In this case, the carboxylate groups were activated with EDC resulting in the active 
intermediate O-acylisourea. Subsequently, the intermediate can react with amine groups present in the 
reaction mixture. After mixing the solution for 1.5 h, the conjugates were purified by ultrafiltration 
(cut-off  100  kDa,  Vivascience)  to  remove  excess  reagent,  by-products  and  non-bound  M12  
(MW~28  kDa).  Finally,  the  conjugates  (shortly  named:  M12-ucNP)  were  re-dispersed  in  PBS  
(pH 7.4). As references, the M12 single-chain Fv fragments and the ucNP were treated in the same 
manner  as  applied  in  the  labeling  reaction,  but  without  the  mediator  EDC.  The  number  of  M12  
single-chain Fv fragments bound to the particles is roughly estimated from the specific M12-absorption at 
280 nm  (εM12~44.3 kM
−1cm
−1) using the 100 k-filtrates of the  conjugates  and the unlabeled M12 
reference. The intensity of the absorption at 280 nm was measured with a commercial spectrometer Int. J. Mol. Sci. 2012, 13  4164 
 
 
from Perkin Elmer (lambda9). The concentration of the M12 single-chain Fv fragments was calculated 
from the absorption and the extinction coefficient according to Lambert-Beer’s law. 
3.9. MUC-1 Expression Profiles of Cancer Cell Lines 
Cell lines were cultured under standard conditions according to the suppliers’ recommendations 
(AATC  protocols,  LGC  Standards  GmbH,  Wesel,  Germany).  Western  blotting  was  performed  as 
described  elsewhere  [5].  Shortly,  a  MUC-1  specific  antibody  (C595  Mouse  anti  Human  MUC-1 
Antibody, AbD Serotec, Duesseldorf, Germany; 1 µg/µL) was used to check the expression of the 
MUC-1  antigen  of  MDA-MB-231  (ATCC:  HTB-26),  DU4475  (ATCC:  HTB-123),  BT-20  (ATCC:  
HTB-19), MCF-7 (ATCC: HTB-22), SK-BR-3 (ATCC: HTB-30), HT-1080 (ATCC: CCL-121) and 
MDA-MB-435 (ATCC: HTB-129) cell lines, respectively. Results were validated via semi-quantitative 
RT-PCR using the forward primer MUC-1-for (GTG CCC CCT AGC AGT ACC G) and the reverse 
primer  MUC-1-rev  (GAC  GTG  CCC  CTA  CAA  GTT  GG;  Eurofins  MWG  Operon,  Ebersberg, 
Germany). The annealing was conducted at 61 ° C followed by an elongation step at 72 ° C using 
TripleMaster DNA-Polymerase (Eppendorf AG, Hamburg, Germany) with 35 repetition steps. DNA 
gel electrophoresis was performed using a 1.5% (w/v) agarose gel and bands were captured with the 
Gel Logic 200 system (Carestream Molecular Imaging, Carestream Health Inc, Woodbridge, CT, USA). 
3.10. In Vitro Binding Studies 
Binding of the M12-ucNP conjugate probe to selected cancer cell lines (HT-1080, MDA-MB-231 
and MDA-MB-435) was checked via laser scanning microscopy (Zeiss LSM 510 Meta Carl Zeiss Jena 
GmbH,  Jena,  Germany)  combined  with  the  Ti:Sapphire  Laser  Chameleon-Ultra  by  Coherent 
Deutschland GmbH (Dieburg, Germany). The laser excitation wavelength was 974 nm, the laser pulse 
width 140 femtoseconds, with a repetition rate of 80 MHz and the power at 974 nm was about 0.8 W. 
1 ×  10
6 cells were carefully washed with PBS buffer solution (pH 7.2, 0.01% Tween 20) and incubated 
in PBS/BSA (pH 7.2, 1% BSA) for 1 h on ice. After washing with PBS the cells were incubated for  
1 h with M12-ucNPs probe and non-labeled ucNPs, respectively. Subsequently, cells were washed  
and imaged.  
3.11. Tumor Xenografts 
All animal studies were approved by the institutional review boards (# G76/2005). Female athymic 
nude mice (nu/nu) were obtained from Charles River Laboratories (Erkrath, Germany). At 4–6 weeks 
of age, 3 ×  10
6 MDA-MB-231 cells suspended in 100 µL PBS were injected subcutaneously into the 
mama fat pad. When tumors reached 4–6 mm in diameter, the tumor-bearing mice were anaesthetized 
by i.p. injection of ketamine (125 mg/kg body weight) and xylazine (12.5 mg/kg bw) and subjected to 
in vivo imaging studies. 
3.12. In Vivo Fluorescence Reflectance Imaging 
Fluorescence images were acquired using the modified small animal in vivo Imaging Station MS 
FX PRO (Carestream Molecular Imaging/Carestream Health, Woodbride, CT, USA). The Xenon lamp Int. J. Mol. Sci. 2012, 13  4165 
 
 
was replaced by a continuous wave 978 nm laser diode (LYPE 30-SG-WL978-F400 by Roithner, 
Austria). A 850 nm cut off filter (Roithner, Austria) in front of the optics was used to block near 
infrared wavelength. Non-conjugated ucNP were injected intramuscularly into mice to check their 
imaging abilities (final concentration 0.1 µM). M12-ucNPs were injected into MDA-MB-231 bearing 
nude mice with a final concentration of 1 mM via a 150 µL i.v. tail vein injection and images were 
captured 30 min after injection. Acquisition times were 300 s at f-stop 2.5. 
4. Conclusions  
In this proof of principle investigation, an anti-MUC-1 single-chain Fv fragment was produced, 
purified and labeled to newly designed surface modified upconversion nanoparticles for in vitro and  
in vivo imaging approaches. The binding of the M12-ucNP probe could be verified in vitro as well as 
in  an initial  experiment  in  vivo. Tumor signal  accumulation of M12-ucNPs  in  a xenograft model 
showed the feasibility of this approach but demonstrate the need for further improvements on the 
instrumentation as well the probe and fluorophore side.  
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